1. Acknowledgements

   Acknowledgement to Referees 19 November 2014 Pages: 1147 - 1150

2. Cost of Illness: An Ongoing Battle Worth Fighting

   • Paul E. Greenberg

   Editorial 10 September 2014 Pages: 1151 - 1152

3. “Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies

   • Steven Kymes

   Current Opinion 13 August 2014 Pages: 1153 - 1155

4. A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials

   • Rita Faria
   • Manuel Gomes
   • Ian R. White

   Practical Application Open access 29 July 2014 Pages: 1157 - 1170

   

5. Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

   • Nicholas R. Latimer
   • Christopher Carroll
   • Raashid Luqmani

   Review Article Open access 25 July 2014 Pages: 1171 - 1183

   

6. A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions

   • Rachel A. Elliott
   • Koen Putman
   • Lieven Annemans

   Review Article 22 August 2014 Pages: 1185 - 1199

7. A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments

   • Andrew Messali
   • Reginald Villacorta
   • Joel W. Hay

   Review Article 02 August 2014 Pages: 1201 - 1212

8. The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review

   • Erika Wissinger
   • Ingolf Griebsch
   • Chris L. Pashos

   Systematic Review 22 August 2014 Pages: 1213 - 1229

   

9. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer

   • Steven R. Alberts
   • Tiffany M. Yu
   • John Hornberger

   Original Research Article Open access 26 August 2014 Pages: 1231 - 1243

   

10. Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

    • Afschin Gandjour

    Letter to the Editor 25 September 2014 Pages: 1245 - 1246

11. Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

    • A. T. Newall
    • M. Jit
    • R. Hutubessy

    Letter to the Editor 06 November 2014 Pages: 1247 - 1247

12. Objectivity and Equity: Clarity Required. A Response to Hill and Olson

    • Mike Paulden
    • James F. O’Mahony
    • Christopher McCabe

    Letter to the Editor 21 November 2014 Pages: 1249 - 1250